









Markets
/
Stocks
/
nasdaq-lqda
/

Liquidia Corp

LQDA

43.040USD

+1.480+3.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.74BMarket Cap

LossP/E TTM



Liquidia Corp

43.040

+1.480+3.56%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Liquidia Corp

Currency: USD Updated: 2026-02-06

Key Insights

Liquidia Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Liquidia Corp's Score

Industry at a Glance

Industry Ranking

30 / 159

Overall Ranking

87 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Liquidia Corp Highlights

StrengthsRisks

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.00M.

Undervalued

The company’s latest PE is -30.07, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 63.88M shares, decreasing 2.95% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 20.27K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.30.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

45.667

Target Price

+2.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Liquidia Corp is 8.92, ranking 27 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 54.34M, representing a year-over-year increase of 1121.72%, while its net profit experienced a year-over-year increase of 84.74%.

Score

Industry at a Glance

Previous score

8.92

Change



Financials

6.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Liquidia Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Liquidia Corp is 6.83, ranking 111 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -30.07, which is -79.83% below the recent high of -6.07 and -8.34% above the recent low of -32.58.

Score

Industry at a Glance

Previous score

6.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Liquidia Corp is 8.22, ranking 52 out of 159 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 67.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.22

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

45.667

Target Price

+2.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Liquidia Corp

LQDA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Liquidia Corp is 9.49, ranking 22 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 50.00 and the support level at 32.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.35

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.077

Neutral

RSI(14)

59.115

Neutral

STOCH(KDJ)(9,3,3)

44.562

Sell

ATR(14)

2.594

Low Volatility

CCI(14)

30.744

Neutral

Williams %R

40.333

Buy

TRIX(12,20)

1.067

Sell

StochRSI(14)

17.660

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

43.974

Sell

MA10

43.192

Sell

MA20

41.009

Buy

MA50

36.460

Buy

MA100

30.557

Buy

MA200

24.524

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Liquidia Corp is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 73.42%, representing a quarter-over-quarter increase of 4.71%. The largest institutional shareholder is The Vanguard, holding a total of 4.00M shares, representing 4.60% of shares outstanding, with 13.84% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Farallon Capital Management, L.L.C.

8.57M

+25.37%

Caligan Partners, LP

8.12M

Manning (Paul B.)

6.16M

+0.30%

BlackRock Institutional Trust Company, N.A.

4.57M

+7.15%

The Vanguard Group, Inc.

Star Investors

3.95M

+10.27%

Findell Capital Management LLC

2.83M

-5.67%

Goldman Sachs & Company, Inc.

2.66M

+13.71%

Opaleye Management Inc.

2.62M

+5.66%

Jeffs (Roger A)

2.11M

-0.30%

State Street Investment Management (US)

1.91M

+4.54%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Liquidia Corp is 5.50, ranking 65 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.